Track topics on Twitter Track topics that are important to you
Lund, December 5, 2018 - SenzaGen (Nasdaq First North: SENZA) today announced that the company has recruited Tina Dackemark Lawesson as communications director. Dackemark Lawesson joins SenzaGen with a wealth of experience from IR and communications positions in similar life science companies and takes up her position in December 2018.
"SenzaGen is in a very exciting development phase and we need to strengthen our organization within both IR and strategic communication. In her role as communications director, Tina will be tasked with increasing communication towards our prioritized target groups and will thus have a key position in SenzaGen," says Anki Malmborg Hager, CEO of SenzaGen.
Dackemark Lawesson joins SenzaGen from Invisio, a Danish communication equipment company based in Copenhagen, where she was Director of Investor Relations & Corporate Communications. She previously held similar positions at Cellavision, Enzymatica and Precise Biometrics.
"SenzaGen is a very exciting company which, thanks to its technology, has the opportunity to make a real impact in the pharmaceutical and cosmetics industries. I am therefore delighted to have the opportunity of meeting the challenge of taking the company's communications forward," says Dackemark Lawesson.
GARD® is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability.
This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in Delaware USA. For more information visit www.senzagen.com
The information was submitted for publication, through the contact person set out above on December 5, 2018, at 08.30.
SenzaGen AB is listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com
Bioscience - any of the sciences that deal with living organisms. The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...